All News
Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc and UCTD most common. @RheumNow #ACR22 Abstr#0832 https://t.co/OU2hFn3ioK https://t.co/Ve0Jbexycm
Richard Conway RichardPAConway ( View Tweet)
Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2
Richard Conway RichardPAConway ( View Tweet)
Johnson et al TYK2i deucravacitinib does not inhibit haematologic pathways, Treg function, or IL-15 dependent NK cell function, that JAKi do. @rheumnow #ACR22 Abstr#0584 https://t.co/UTHzUjGmJN https://t.co/NUKKAv3tAr
Richard Conway RichardPAConway ( View Tweet)
Severe non-adherence to HCQ independently assoc'd w/ risk of SLE flare in the following year, with early damage, and 5-year mortality. Abs 0343 #ACR22 @RheumNow https://t.co/JYRWD5QIlf https://t.co/UCWYrHIc4b
Dr. Rachel Tate uptoTate ( View Tweet)
Gopal et al. Withdrawal of immunosuppressants non-inferior to steroid withdrawal in SLE in clinical remission. Numerically higher flare rate in steroid withdrawal group 15 vs 7 (RR 2.1). @RheumNow #ACR22 Abstr#0997 https://t.co/psoHvg0pVG https://t.co/GlsDjpgXGo
Richard Conway RichardPAConway ( View Tweet)
Giblon et al. Incidence depression and anxiety in RA over 30 years. No change in depression, significant increase in anxiety @RheumNow #ACR22 Abstr#0886 https://t.co/1a3sayBEnl https://t.co/jflc3UTbIh
Richard Conway RichardPAConway ( View Tweet)
Bui et al. Outcomes in Adult onset Stills Disease. >40% required ICU admission and 3.5% died in this retrospective study. No effect of concomittent pneumonia. @RheumNow #ACR22 Abstr#0829 https://t.co/YxkXJJ7EGR https://t.co/mMbQ14iRL1
Richard Conway RichardPAConway ( View Tweet)
Madan et al. Ferritin levels more than 7511 and ferritin/ CRP levels more than 204.5 was associated with higher mortality in Macrophage Activation Syndrome @RheumNow #ACR22 Abstr#0825 https://t.co/jL58oCCEWa https://t.co/9V4PW49EyC
Richard Conway RichardPAConway ( View Tweet)
Ma et al. Calprotectin differentiates remission and low disease activity in RA. @RheumNow #ACR22 Abstr#0884 https://t.co/z9oeKPLq5z https://t.co/YFkIBEqT0c
Richard Conway RichardPAConway ( View Tweet)
Sarilumab in GC resistant PMR
🔥SAPHYR🔥
👉Arm 1- sar 200mg Q2W + 14wk GC
👉 Arm 2- PBO Q2W + 52wk GC
🌟RESULTS🌟
💪🏻 Arm 1 - PMR symp + signs ⬇️ wk 2 with continued improvement until wk 52
🌟Arm 1- ⬇️ chance flare post achieving remission
#ACR22 @RheumNow https://t.co/tXQuuoAelP
Patricia Harkins DrTrishHarkins ( View Tweet)
CLE to SLE transition occurred more frequently in pts aged 40 and younger, w/in the first 10 years of dx, and those with SCLE. Abs 0338 #ACR22 @RheumNow https://t.co/XxHjkNL5Hf https://t.co/1WtgmVM7Iz
Dr. Rachel Tate uptoTate ( View Tweet)
Saxena et al Zetomipzomib, a selective immunoproteasome inhibitor in lupus nephritis. Phase 2 study. UPCR=<0.5 achieved 64.7% week 37, pred=<10mg/day 82.4% week 13. @RheumNow #ACR22 Abstr#0992 https://t.co/askpmqsYYG https://t.co/cKoR0bgtWt
Richard Conway RichardPAConway ( View Tweet)
Wallace @zach_wallace_md et al. IgG4-RD in USA. Incidence 1.2/100,000, prevalence 2.8/100,000. Pancreas (43.0%), biliary tract (30.6%), salivary glands (11.7%), retroperitoneum (5.0%). HR 2.51 for mortality in IgG4-RD. @RheumNow #ACR22 Abstr#0713 https://t.co/IpjSKxmHQN
Richard Conway RichardPAConway ( View Tweet)
Opioid use in adults with PsA and AS
Abstract #0402 @RheumNow #ACR22
✋828 PsA patients ➡️ 21% used opioids
🦴 334 AS patients ➡️ 27% used opioids
💊Opioid users had more comorbidities, more medical visits, worse disease activity, and higher prevalence of 🚬
Catherine Sims, MD DrCassySims ( View Tweet)
Manansala et al. Baseline lymphopenia negatively predicts disease severity in sarcoid. It is protective for decline in FBC. @RheumNow #ACR22 Abstr#0830 https://t.co/Q4fE9LoG9L https://t.co/Tt1PyYLfWu
Richard Conway RichardPAConway ( View Tweet)
Ross et al. Comorbid liver disease significantly attenuates CRP rise with disease flare. Increased BMI increases CRP rise. @RheumNow #ACR22 Abstr#0811 https://t.co/O3PsDfbCMV https://t.co/9xAqWTJqkf
Richard Conway RichardPAConway ( View Tweet)
Fat and bone health are related via adipokines (fat hormones).
Data from VA registry of RA pts:
clear relationship between elevated adipokines & osteoporotic fracture risk.
This is why body fat should be a target for osteoporosis management
ABST0889 @PennRheum #ACR22 @RheumNow https://t.co/BoP8d4sooZ
David Liew drdavidliew ( View Tweet)
Vural et al Rituximab biosimilar switch in GPA. Essentially it is the same. @RheumNow #ACR22 Abstr#1072 https://t.co/OBOMz35soX https://t.co/dPdcWQmBzd
Richard Conway RichardPAConway ( View Tweet)
Soussi et al. Over last 20 years, 5-year all-cause morality decreased in RA and controls in Danish study. But to greater extent in RA, narrowing mortality gap. @RheumNow #ACR22 Abstr#0711 https://t.co/JRh37u3uGm https://t.co/bA3Y5FLcRZ
Richard Conway RichardPAConway ( View Tweet)
Have you heard of MyPROSLE (available at https://t.co/a4zlBtwaaC)? Abs 0329 details MyPROSLE's molecular characterization of individual SLE pts and it's extraction of key molecular information to support more precise therapeutic decisions. #ACR22 @RheumNow https://t.co/FslQCVvptw https://t.co/NNlgZvllPC
Links:
Dr. Rachel Tate uptoTate ( View Tweet)